Bayer launches Aleve PM; Canada green-lights BMS' Yervoy;

> Bayer has launched Aleve PM, a pain reliever and sleep-aid combo. Release

> Health Canada has approved Bristol-Myers Squibb's ($BMY) Yervoy for first-line treatment of adults with metastatic melanoma. Release

> Novo Nordisk's ($NVO) new long-acting insulin, Tresiba, is effective and safe for long-term use in children and young adults with Type 1 diabetes, a new study shows. Report

> Danish drugmaker Lundbeck has launched antidepressant Brintellix in its home market, its first EU rollout. Report

> AbbVie ($ABBV) and Biogen Idec's ($BIIB) experimental multiple sclerosis med Zinbryta topped Biogen's Avonex on some measures in a Phase III trial. More

> Almost 90 lives could be saved every year if almost all teenage girls were given HPV vaccinations, experts say. More

And Finally... The U.S. government says Bayer makes unproven statements about the health benefits of a popular probiotic. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?